Premium
In vitro activity of chloramphenicol, florfenicol and enrofloxacin against Chlamydia pecorum isolated from koalas ( Phascolarctos cinereus )
Author(s) -
Black LA,
Higgins DP,
Govendir M
Publication year - 2015
Publication title -
australian veterinary journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.382
H-Index - 59
eISSN - 1751-0813
pISSN - 0005-0423
DOI - 10.1111/avj.12364
Subject(s) - florfenicol , enrofloxacin , chloramphenicol , biology , microbiology and biotechnology , chlamydia , phascolarctos cinereus , minimum inhibitory concentration , antibiotics , virology , ciprofloxacin , medicine , immunology , population , environmental health
Objective To determine the in vitro susceptibilities of koala isolates of Chlamydia pecorum to enrofloxacin and chloramphenicol, which are frequently used to treat koalas with chlamydiosis, and florfenicol, a derivative of chloramphenicol. Methods The in vitro susceptibilities were determined by culturing three stored isolates and seven clinical swabs of C. pecorum. Susceptibility testing was undertaken using cycloheximide‐treated buffalo green monkey kidney cells in 96 well microtitre plates. Results The minimum inhibitory concentrations (MICs) for all isolates were 0.25–0.50 µg/mL (enrofloxacin), 1–2 µg/mL (chloramphenicol), and 1–2 µg/mL (florfenicol). Minimum bactericidal concentration (MBC) values for five isolates were also determined and were within one two‐fold dilution of MICs. The MICs and MBCs of these antimicrobials were within ranges previously reported for other chlamydial species. Conclusion When combined with previously published pharmacokinetic data, the in vitro susceptibility results support chloramphenicol as a more appropriate treatment option than enrofloxacin for koalas with chlamydiosis. The susceptibility results also indicate florfenicol may be an appropriate treatment option for koalas with chlamydiosis, warranting further investigation.